Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BETA Technologies, Inc.BETA · Entity 1930 | Director | June 11, 2026 | June 12, 2026 |
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director · Chairperson & CEO | October 13, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BETA Technologies, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 8,213 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 7,142 · Balance 8,213 |
UNITED THERAPEUTICS Corp
Report date October 13, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 333,943 |
Reported balance
After 2026-10-13 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-10-13 · Exercise / conversion · Acquired 9,500 · Balance 333,943 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 333,304 |
Reported balance
After 2026-10-13 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-10-13 · Sale · Disposed 639 · Balance 333,304 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 330,964 |
Reported balance
After 2026-10-13 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-10-13 · Sale · Disposed 2,340 · Balance 330,964 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 329,472 |
Reported balance
After 2026-10-13 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-10-13 · Sale · Disposed 1,492 · Balance 329,472 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 327,965 |
Reported balance
After 2026-10-13 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2026-10-13 · Sale · Disposed 1,507 · Balance 327,965 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 326,513 |
Reported balance
After 2026-10-13 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2026-10-13 · Sale · Disposed 1,452 · Balance 326,513 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 325,883 |
Reported balance
After 2026-10-13 transaction · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · 2026-10-13 · Sale · Disposed 630 · Balance 325,883 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 325,185 |
Reported balance
After 2026-10-13 transaction · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · 2026-10-13 · Sale · Disposed 698 · Balance 325,185 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,683 |
Reported balance
After 2026-10-13 transaction · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · 2026-10-13 · Sale · Disposed 502 · Balance 324,683 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,523 |
Reported balance
After 2026-10-13 transaction · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · 2026-10-13 · Sale · Disposed 160 · Balance 324,523 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,443 |
Reported balance
After 2026-10-13 transaction · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · 2026-10-13 · Sale · Disposed 80 · Balance 324,443 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 249,108 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 249,108 F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 45,596 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 45,596 F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 8,902 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 8,902 F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.76 · Expires 2027-03-15 | Indirectby Trust | 242,910 |
Reported balance
After 2026-10-13 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-10-13 · Exercise / conversion · Disposed 9,500 · Balance 242,910 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023. F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Direct | 40,513 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 40,513 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 166 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 166 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2017 Filed Oct 16, 2017 12:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 914 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-029821 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,377 Underlying: Common Stock · 914 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 12:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 1,263 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-029821 · form4.xml · derivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,291 Underlying: Common Stock · 1,263 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 12:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 914 | $30.75 | $28,105.50 |
DisclosureSEC source: 0001127602-17-029821 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 677,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 12:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,263 | $120.20 | $151,813.11 |
DisclosureSEC source: 0001127602-17-029821 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $119.78 to $120.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 12:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,263 | $30.75 | $38,837.25 |
DisclosureSEC source: 0001127602-17-029821 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 20:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 920 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-029564 · form4.xml · derivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,554 Underlying: Common Stock · 920 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 20:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 1,256 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-029564 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,474 Underlying: Common Stock · 1,256 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 20:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $123.69 | $24,738.00 |
DisclosureSEC source: 0001127602-17-029564 · form4.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $123.66 to $123.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 20:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 856 | $123.05 | $105,332.68 |
DisclosureSEC source: 0001127602-17-029564 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,269 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $122.56 to $123.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 20:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $121.94 | $24,388.00 |
DisclosureSEC source: 0001127602-17-029564 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,125 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $121.49 to $122.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 20:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 920 | $30.75 | $28,290.00 |
DisclosureSEC source: 0001127602-17-029564 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 676,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 20:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,256 | $30.75 | $38,622.00 |
DisclosureSEC source: 0001127602-17-029564 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 20:01 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 912 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-028503 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,730 Underlying: Common Stock · 912 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 20:01 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 1,265 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-028503 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,642 Underlying: Common Stock · 1,265 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 20:01 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 506 | $120.08 | $60,762.81 |
DisclosureSEC source: 0001127602-17-028503 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $119.93 to $120.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 20:01 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 759 | $119.44 | $90,652.76 |
DisclosureSEC source: 0001127602-17-028503 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $118.95 to $119.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 20:01 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 912 | $30.75 | $28,044.00 |
DisclosureSEC source: 0001127602-17-028503 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 675,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 20:01 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,265 | $30.75 | $38,898.75 |
DisclosureSEC source: 0001127602-17-028503 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 12:04 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 902 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-027906 · form4.xml · derivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,907 Underlying: Common Stock · 902 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 12:04 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 1,274 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-027906 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,809 Underlying: Common Stock · 1,274 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 12:04 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $117.36 | $23,472.00 |
DisclosureSEC source: 0001127602-17-027906 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $117.23 to $117.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 12:04 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,074 | $115.83 | $124,396.48 |
DisclosureSEC source: 0001127602-17-027906 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,269 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $115.48 to $116.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 12:04 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 902 | $30.75 | $27,736.50 |
DisclosureSEC source: 0001127602-17-027906 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 674,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| September 21, 2017 Filed Sep 22, 2017 12:04 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,274 | $30.75 | $39,175.50 |
DisclosureSEC source: 0001127602-17-027906 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 20:08 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 919 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-027493 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,083 Underlying: Common Stock · 919 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 20:08 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 1,258 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-027493 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,002 Underlying: Common Stock · 1,258 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 20:08 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 400 | $122.56 | $49,024.00 |
DisclosureSEC source: 0001127602-17-027493 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $122.44 to $122.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 20:08 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 858 | $121.85 | $104,550.82 |
DisclosureSEC source: 0001127602-17-027493 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,469 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $121.41 to $122.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 20:08 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 919 | $30.75 | $28,259.25 |
DisclosureSEC source: 0001127602-17-027493 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 673,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 20:08 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,258 | $30.75 | $38,683.50 |
DisclosureSEC source: 0001127602-17-027493 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 21:51 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 944 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-027204 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,260 Underlying: Common Stock · 944 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 21:51 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 1,232 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-027204 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,204 Underlying: Common Stock · 1,232 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 21:51 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 517 | $133.71 | $69,126.62 |
DisclosureSEC source: 0001127602-17-027204 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $133.48 to $134.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 21:51 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 715 | $133.05 | $95,129.68 |
DisclosureSEC source: 0001127602-17-027204 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,586 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $132.44 to $133.385. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 21:51 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 944 | $30.75 | $29,028.00 |
DisclosureSEC source: 0001127602-17-027204 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 672,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 21:51 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,232 | $30.75 | $37,884.00 |
DisclosureSEC source: 0001127602-17-027204 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 21:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 942 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-026843 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,436 Underlying: Common Stock · 942 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 21:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 1,235 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-026843 · form4.xml · derivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,378 Underlying: Common Stock · 1,235 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 21:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,235 | $130.49 | $161,155.77 |
DisclosureSEC source: 0001127602-17-026843 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $129.93 to $130.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 21:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 942 | $30.75 | $28,966.50 |
DisclosureSEC source: 0001127602-17-026843 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 671,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 21:09 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,235 | $30.75 | $37,976.25 |
DisclosureSEC source: 0001127602-17-026843 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 20:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 938 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-026496 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,613 Underlying: Common Stock · 938 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 20:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 1,238 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-026496 · form4.xml · derivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,551 Underlying: Common Stock · 1,238 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 20:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,238 | $130.65 | $161,738.88 |
DisclosureSEC source: 0001127602-17-026496 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $130.31 to $130.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 20:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 938 | $30.75 | $28,843.50 |
DisclosureSEC source: 0001127602-17-026496 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 670,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 20:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,238 | $30.75 | $38,068.50 |
DisclosureSEC source: 0001127602-17-026496 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| August 17, 2017 Filed Aug 17, 2017 20:49 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 942 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-025938 · form4.xml · derivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,789 Underlying: Common Stock · 942 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| August 17, 2017 Filed Aug 17, 2017 20:49 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 1,235 | $0.00 Strike: $30.75 | $0.00 |
DisclosureSEC source: 0001127602-17-025938 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,731 Underlying: Common Stock · 1,235 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. Read SEC document |
| August 17, 2017 Filed Aug 17, 2017 20:49 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 942 | $30.75 | $28,966.50 |
DisclosureSEC source: 0001127602-17-025938 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 669,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F2 · price: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009. Read SEC document |
| August 17, 2017 Filed Aug 17, 2017 20:49 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $132.71 | $26,541.00 |
DisclosureSEC source: 0001127602-17-025938 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069 F1 · kind: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $132.62 to $132.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.